A rich history dating back to 1715 has moulded GlaxoSmithKline into an internationally recognised pharmaceuticals, vaccines, healthcare and biologics conglomerate. Once famous for drugs including Zantac and Zovirax, its strategy centres around a diversified global business, delivering valuable products while simplifying its operating approach to help people live longer. The company has a portfolio of products for diseases including cancer, AIDS, asthma, diabetes, as well as products for mental health conditions. This year the company purchased a stake in biotech start-up Autifony Therapeutics and announced positive top results for its Phase III IPX066 Parkinson’s disease study. The company returns to the World Finance 100 having made the grade in 2010.